Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review

Autoimmunity Reviews

Volumn 16, Issue 3, 2017, Pages 287-293

  Sciascia, S ^a   Radin, M ^a   Yazdany, J ^b   Levy, R A ^c   Roccatello, D ^a   Dall'Era, M ^b   Cuadrado, M J ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CREATININE; MONOCLONAL ANTIBODY;

CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; PROTEINURIA; REVIEW; SLEDAI; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; ADULT; DRUG EFFECTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; YOUNG ADULT;

EID: 85011311255     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.01.010     Document Type: Review

References (34)

1. [1] Navarra, S.V., Guzmán, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731, 10.1016/S0140-6736(10)61354-2.
2. [2] Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzová, D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63 (2011), 3918–3930, 10.1002/art.30613.
3. [3] Kasitanon, N., Magder, L.S., Petri, M., Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85 (2006), 147–156, 10.1097/01.md.0000224709.70133.f7.
4. [4] Bernatsky, S., Boivin, J.-F., Joseph, L., Manzi, S., Ginzler, E., Gladman, D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54 (2006), 2550–2557, 10.1002/art.21955.
5. [5] Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., FitzGerald, J.D., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64 (2012), 797–808, 10.1002/acr.21664.
6. [6] Ward, M.M., Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol 36 (2009), 63–67, 10.3899/jrheum.080625.
7. [7] Parodis, I., Zickert, A., Sundelin, B., Axelsson, M., Gerhardsson, J., Svenungsson, E., et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med, 2, 2015, e000061, 10.1136/lupus-2014-000061.
8. [8] Neusser, M.A., Lindenmeyer, M.T., Edenhofer, I., Gaiser, S., Kretzler, M., Regele, H., et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24 (2011), 98–107, 10.1038/modpathol.2010.184.
9. [9] Petri, M.A., van Vollenhoven, R.F., Buyon, J., Levy, R.A., Navarra, S.V., Cervera, R., et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 65 (2013), 2143–2153, 10.1002/art.37995.
10. [10] Bassi, N., Luisetto, R., Ghirardello, A., Gatto, M., Valente, M., Della Barbera, M., et al. 17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. Lupus 24 (2015), 382–391, 10.1177/0961203314559636.
11. [11] Ding, H., Wang, L., Wu, X., Yan, J., He, Y., Ni, B., et al. Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J Cell Mol Med 14 (2010), 1717–1725, 10.1111/j.1582-4934.2009.00817.x.
12. [12] Dooley, M.A., Houssiau, F., Aranow, C., D'Cruz, D.P., Askanase, A., Roth, D.A., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22 (2013), 63–72, 10.1177/0961203312465781.
13. [13] Fließer, E., Korsten, P., Koziolek, M., Niewold, T., Patschan, D., Muller, G., et al. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with belimumab in a 19-year-old woman. Lupus 22 (2013), 1523–1525, 10.1177/0961203313504145.
14. [14] De Scheerder, M.A., Boey, O., Mahieu, E., Vanuytsel, J., Bogaert, A.M., Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant. Clin Rheumatol 35 (2016), 1649–1653, 10.1007/s10067-015-3153-1.
15. [15] Gonzalez-Echavarri, C., Ugarte, A., Ruiz-Irastorza, G., Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol, 34(2), 2016, 355, 10.1111/j.1365-2125.2007.02971.x.
16. [16] Simonetta, F., Allali, D., Roux-Lombard, P., Chizzolini, C., Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine, 1–2, 2016, 10.1016/j.jbspin.2016.01.008.
17. [17] Kraaij, T., Huizinga, T.W.J., Rabelink, T.J., Teng, Y.K.O., Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 53 (2014), 2122–2124, 10.1093/rheumatology/keu369.
18. [18] Askanase, Anca, Reddy, Arthi, Buyon, Jill P., Franks, A.G., Furie, Richard A., Kamen, Diane L., et al. Favorable clinical response to belimumab at three months. Arthritis Rheum, 2013, 1574.
19. [19] Reddy, A., Buyon, J.P., Franks, A.G., Favorable clinical response to belimumab at three months. Ann Rheum Dis, 2013, 257.
20. [20] Parodis, I., Svenungsson, E., Axelsson, M., Gunnarsson, I., AB0487 decreased SLE disease activity and corticosteroid usage and NO renal flares during belimumab treatment. Ann Rheum Dis 73 (2014), 968.2–96968, 10.1136/annrheumdis-2014-eular.3876.
21. [21] Parodis, I., Svenungsson, E., Axelsson, M., Gunnarsson, I., Renal, decreased disease activity and corticosteroid usage and no lupus, flares during belimumab treatment in patients with systemic 670, erythematosus-abstract. Arthritis Rheum, 2014 [http://acr].
22. [22] Danve, A., Perry, L., Deodhar, A., Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-a case report. Semin Arthritis Rheum 44 (2015), 195–197, 10.1016/j.semarthrit.2014.05.006.
23. [23] Parodis, I., Sjöwall, C., Jönsen, A., Zickert, A., Frodlund, M., Ramsköld, D., et al. Decreased disease activity and corticosteroid usage and improved quality of life during belimumab treatment in patients with systemic lupus erythematosus – a prospective real-life observational study. Arthritis Rheum, 67, 2015.
24. [24] Brito Zeron, P., Caminal-Montero, L., Chamorro, A., de la Hera, Fernández J., Gato, A., Marín-Ballvé, A., et al. AB0542 blocking the human B lymphocyte stimulator molecule (BLYS) using a monoclonal antibody (belimumab) in systemic lupus erythematosus: first results in real-life Spanish patients with refractory disease (Biogeas-semi registry). Ann Rheum Dis 73 (2014), 985.2–98985, 10.1136/annrheumdis-2014-eular.5447.
25. [25] Mohan, S., Barsalou, J., Bradley, T.J., Slorach, C., Reynolds, J.A., Hasni, S., et al. Favorable response to belimumab at three months. Arthritis Rheum 67 (2015), 2257–2262, 10.1002/art.39149.
26. [26] Roccatello, D., Sciascia, S., Baldovino, S., Rossi, D., Alpa, M., Naretto, C., et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment. Autoimmun Rev, 2015, 10.1016/j.autrev.2015.07.017.
27. [27] Sciascia, S., Talavera-Garcia, E., Roccatello, D., Baldovino, S., Mengatti, E., Cuadrado, M.J., Upcoming biological therapies in systemic lupus erythematosus. Int Immunopharmacol 27 (2015), 189–193, 10.1016/j.intimp.2015.04.049.
28. [28] Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Baldovino, S., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant, 26, 2011, 10.1093/ndt/gfr109.
29. [29] Leone, A., Sciascia, S., Kamal, A., Khamashta, M., Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 11 (2015), 109–116, 10.1586/1744666X.2015.994508.
30. [30] Zhang, H., Chambers, W., Sciascia, S., Cuadrado, M.J., Emerging therapies in systemic lupus erythematous: from clinical trial to the real life. Expert Rev Clin Pharmacol 9 (2016), 681–694, 10.1586/17512433.2016.1155446.
31. [31] Manzi, S., Sanchez-Guerrero, J., Merrill, J.T., Furie, R., Gladman, D., Navarra, S.V., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71 (2012), 1833–1838, 10.1136/annrheumdis-2011-200831.
32. [32] Sjöwall, C., Cöster, L., Belimumab may not prevent lupus nephritis in serologically active patientswith ongoing non-renal disease activity may not prevent lupus nephritis in serologically active patientswith ongoing non-renal disease activity. Scand J Rheumatol 5 (2014), 428–430, 10.3109/03009742.2014.887769.
33. [33] Hanly, J.G., O'Keeffe, A.G., Su, L., Urowitz, M.B., Romero-Diaz, J., Gordon, C., et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55 (2016), 252–262, 10.1093/rheumatology/kev311.
34. [34] Rovin, B.H., Kindey involvement in SLE. Lahita, R., (eds.) Systemic lupus erythematosus, 5th ed., 2011, Acad. Press, San Diego, CA, USA, 769–814.